- Home
- TGEN vs CTNM Comparison
TGEN vs CTNM Comparison
Compare TGEN & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGEN
- CTNM
- Stock Information
- Founded
- TGEN 2000
- CTNM 2009
- Country
- TGEN United States
- CTNM United States
- Employees
- TGEN N/A
- CTNM N/A
- Industry
- TGEN
- CTNM
- Sector
- TGEN
- CTNM
- Exchange
- TGEN NYSE
- CTNM Nasdaq
- Market Cap
- TGEN 146.1M
- CTNM 122.9M
- IPO Year
- TGEN N/A
- CTNM 2024
- Fundamental
- Price
- TGEN $6.21
- CTNM $4.76
- Analyst Decision
- TGEN
- CTNM Strong Buy
- Analyst Count
- TGEN 0
- CTNM 4
- Target Price
- TGEN N/A
- CTNM $22.50
- AVG Volume (30 Days)
- TGEN 389.3K
- CTNM 119.1K
- Earning Date
- TGEN 08-11-2025
- CTNM 08-12-2025
- Dividend Yield
- TGEN N/A
- CTNM N/A
- EPS Growth
- TGEN N/A
- CTNM N/A
- EPS
- TGEN N/A
- CTNM N/A
- Revenue
- TGEN $23,711,209.00
- CTNM N/A
- Revenue This Year
- TGEN $155.81
- CTNM N/A
- Revenue Next Year
- TGEN $19.42
- CTNM N/A
- P/E Ratio
- TGEN N/A
- CTNM N/A
- Revenue Growth
- TGEN N/A
- CTNM N/A
- 52 Week Low
- TGEN $0.65
- CTNM $3.35
- 52 Week High
- TGEN $6.42
- CTNM $22.00
- Technical
- Relative Strength Index (RSI)
- TGEN N/A
- CTNM N/A
- Support Level
- TGEN N/A
- CTNM N/A
- Resistance Level
- TGEN N/A
- CTNM N/A
- Average True Range (ATR)
- TGEN 0.00
- CTNM 0.00
- MACD
- TGEN 0.00
- CTNM 0.00
- Stochastic Oscillator
- TGEN 0.00
- CTNM 0.00
About TGEN TECOGEN INC
Tecogen Inc, designs, manufactures, markets, and maintains high-efficiency, ultra-clean cogeneration products. It operates in three business segments, namely Products, Services, and Energy Production. Products segment designs, manufactures, and sells industrial and commercial cogeneration systems. The services segment provides operations and maintenance services and turn-key installation for products under long-term service contracts. The Energy Production segment sells energy in the form of electricity, heat, hot water, and cooling to the customers under long-term energy sales agreements.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.